The detection and management of early HIV infection: A clinical and public health emergency

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue SUPPL. 2, 2013, Pages

  Smith, M Kumi ^a   Rutstein, Sarah E ^a   Powers, Kimberly A ^a,b   Fidler, Sarah ^c   Miller, William C ^a,b   Eron, Joseph J ^b   Cohen, Myron S ^b  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antiretroviral therapy; Early acute HIV infection; HIV transmission; Treatment as prevention

Indexed keywords

ANTIVIRAL THERAPY; ARTICLE; BEHAVIOR CHANGE; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LONG TERM EXPOSURE; MALE HOMOSEXUAL; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SEXUALITY; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS LOAD; VIRUS REPLICATION;

EID: 84880227489     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31829871e0     Document Type: Article

References (132)

1. Cates W, Chesney MA, Cohen MS. Primary HIV infection-a public health opportunity. Am J Public Health. 1997;87:1928-1930.
2. Epstein H. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet. 2009;373:1078-1079.
3. Wilson DP. Data are lacking for quantifying HIV transmission risk in the presence of effective antiretroviral therapy. AIDS. 2009;23: 1431-1433.
4. Ruark A, Shelton JD, Halperin DT, et al. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet. 2009;373:1078.
5. Cohen MS, Dye C, Fraser C, et al. HIV treatment as prevention: debate and Commentary-will early infection compromise treatment-as-prevention strategies? PLoS Med. 2012;9:e1001232.
6. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A. 2008;105: 7552-7557.
7. Bar KJ, Li H, Chamberland A, et al. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol. 2010;84: 6241-6247.
8. Estes JD, Haase AT, Schacker TW. The role of collagen deposition in depleting CD4+ T cells and limiting reconstitution in HIV-1 and SIV infections through damage to the secondary lymphoid organ niche. Semin Immunol. 2008;20:181-186.
9. Cohen MS, Shaw GM, McMichael AJ, et al. Acute HIV-1 infection. N Engl J Med. 2011;364:1943-1954.
10. Borrow P, Hou S, Gloster S, et al. Virus infection-associated bone marrow B cell depletion and impairment of humoral immunity to het-erologous infection mediated by TNF-alpha/LTalpha. Eur J Immunol. 2005;35:524-532.
11. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871-1879.
12. Brenchley JM, Douek DC. The mucosal barrier and immune activation in HIV pathogenesis. Curr Opin HIV AIDS. 2008;3:356-361.
13. Chun TW, Engel D, Berrey MM, et al. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A. 1998;95:8869-8873.
14. McMichael AJ, Borrow P, Tomaras GD, et al. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol. 2010;10:11-23.
15. Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One. 2012;7:e33948.
16. Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis. 2007;195:951-959.
17. Lavreys L, Baeten JM, Chohan V, et al. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis. 2006; 42:1333-1339.
18. Ma ZM, Stone M, Piatak M, et al. High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol. 2009;83:3288-3297.
19. Pilcher CD, Joaki G, Hoffman IF, et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS. 2007;21:1723-1730.
20. Pilcher CD, Tien HC, Eron JJ, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis. 2004;189: 1785-1792.
21. Morrison CS, Demers K, Kwok C, et al. Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. AIDS. 2010;24:573-582.
22. Pao D, Fisher M, Hué S, et al. Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS. 2005;19:85-90.
23. Colfax GN, Buchbinder SP, Cornelisse PGA, et al. Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS. 2002;16:1529-1535.
24. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006;20:1447-1450.
25. Powers KA, Ghani AC, Miller WC, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet. 2011;378:256-268.
26. Lewis F, Hughes GJ, Rambaut A, et al. Episodic sexual transmission of HIV revealed by molecular phylodynamics. PLoS Med. 2008;5:e50.
27. Yerly S, Vora S, Rizzardi P, et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS. 2001;15: 2287-2292.
28. Dennis AM, Hué S, Hurt CB, et al. Phylogenetic insights into regional HIV transmission. AIDS. 2012;26:1813-1822.
29. Fisher M, Pao D, Brown AE, et al. Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach. AIDS. 2010;24:1739-1747.
30. Brown AE, Gifford RJ, Clewley JP, et al. Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions. J Infect Dis. 2009;199:427-431.
31. Miller WC, Rosenberg NE, Rutstein SE, et al. Role of acute and early HIV infection in the sexual transmission of HIV. Curr Opin HIV AIDS. 2010;5:277-282.
32. Jacquez JA, Koopman JS, Simon CP, et al. Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr. 1994;7:1169-1184.
33. Pinkerton SD, Abramson PR. Implications of increased infectivity in early-stage HIV infection application of a Bernoulli-process model of HIV transmission. Eval Rev. 1996;20:516-540.
34. Koopman JS, Jacquez JA, Welch GW, et al. The role of early HIV infection in the spread of HIV through populations. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:249-258.
35. Kretzschmar M, Dietz K. The effect of pair formation and variable infectivity on the spread of an infection without recovery. Math Biosci. 1998;148:83-113.
36. Coutinho FA, Lopez LF, Burattini MN, et al. Modelling the natural history of HIV infection in individuals and its epidemiological implications. Bull Math Biol. 2001;63:1041-1062.
37. Xiridou M, Geskus R, De Wit J, et al. Primary HIV infection as source of HIV transmission within steady and casual partnerships among homosexual men. AIDS. 2004;18:1311-1320.
38. Pinkerton SD. How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission? AIDS. 2007;21:1625-1629.
39. Prabhu VS, Hutchinson AB, Farnham PG, et al. Sexually acquired HIV infections in the United States due to acute-phase HIV transmission: an update. AIDS. 2009;23:1792-1794.
40. Goodreau SM, Cassels S, Kasprzyk D, et al. Concurrent partnerships, acute infection and HIV epidemic dynamics among young adults in Zimbabwe. AIDS Behav. 2012;16:312-322.
41. Hayes RJ, White RG. Amplified HIV transmission during early-stage infection. J Infect Dis. 2006;193:604-605; author reply 605-606.
42. Eaton JW, Hallett TB, Garnett GP. Concurrent sexual partnerships and primary HIV infection: a critical interaction. AIDS Behav. 2011; 15:687-692.
43. Pinkerton SD. Probability of HIV transmission during acute infection in Rakai, Uganda. AIDS Behav. 2008;12:677-684.
44. Abu-Raddad LJ, Longini IM. No HIV stage is dominant in driving the HIV epidemic in sub-Saharan Africa. AIDS. 2008;22:1055-1061.
45. Salomon JA, Hogan DR. Evaluating the impact of antiretroviral therapy on HIV transmission. AIDS. 2008;22(suppl 1):S149-S159.
46. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis. 2008;198:687-693.
47. Napierala-Mavedzenge S, Gaydos CA, Makombe SD. The uptake and accuracy of oral kits for HIV self-testing in high HIV prevalence setting: a cross-sectional feasibility study in Blantyre, Malawi. PLoS Med. 2011;8:e1001102.
48. Zetola NM, Pilcher CD. Diagnosis and management of acute HIV infection. Infect Dis Clin North Am. 2007;21:19-48, vii.
49. Patel P, Mackellar D, Simmons P, et al. Detecting acute human immunodeficiency virus infection using 3 different screening immunoassays and nucleic acid amplification testing for human immunodeficiency virus RNA, 2006-2008. Arch Intern Med. 2010;170:66-74.
50. Stekler JD, Swenson PD, Coombs RW, et al. HIV testing in a high-incidence population: is antibody testing alone good enough? Clin Infect Dis. 2009;49:444-453.
51. Eshleman SH, Khaki L, Laeyendecker O, et al. Detection of individuals with acute HIV-1 infection using the ARCHITECT HIV Ag/Ab Combo assay. J Acquir Immune Defic Syndr. 2009;52:121-124.
52. Chetty V, Moodley D, Chuturgoon A. Evaluation of a 4th generation rapid HIV test for earlier and reliable detection of HIV infection in pregnancy. J Clin Virol. 2012;54:180-184.
53. Karris MY, Anderson CM, Morris SR, et al. Cost savings associated with testing of antibodies, antigens, and nucleic acids for diagnosis of acute HIV infection. J Clin Microbiol. 2012;50:1874-1878.
54. Quinn TC, Brookmeyer R, Kline R, et al. Feasibility of pooling sera for HIV-1 viral RNA to diagnose acute primary HIV-1 infection and estimate HIV incidence. AIDS. 2000;14:2751-2757.
55. Fiscus SA, Pilcher CD, Miller WC, et al. Rapid, real-time detection of acute HIV infection in patients in Africa. J Infect Dis. 2007;195:416-424.
56. Westreich DJ, Hudgens MG, Fiscus SA, et al. Optimizing screening for acute human immunodeficiency virus infection with pooled nucleic acid amplification tests. J Clin Microbiol. 2008;46:1785-1792.
57. Kerndt PR, Dubrow R, Aynalem G, et al. Strategies used in the detection of acute/early HIV infections. The NIMH Multisite Acute HIV Infection Study: I. AIDS Behav. 2009;13:1037-1045.
58. Hutchinson AB, Patel P, Sansom SL, et al. Cost-effectiveness of pooled nucleic acid amplification testing for acute HIV infection after third-generation HIV antibody screening and rapid testing in the United States: a comparison of three public health settings. PLoSMed. 2010;7:e1000342.
59. Rosenberg NE, Kamanga G, Phiri S, et al. Detection of acute HIV infection: a field evaluation of the determine® HIV-1/2 Ag/Ab combo test. J Infect Dis. 2012;205:528-534.
60. Pavie J, Rachline A, Loze B, et al. Sensitivity of five rapid HIV tests on oral fluid or finger-stick whole blood: a real-time comparison in a healthcare setting. PLoS One. 2010;5:e11581.
61. Powers KA, Poole C, Pettifor AE, et al. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8:553-563.
62. Miller WC, Leone PA, McCoy S, et al. Targeted testing for acute HIV infection in North Carolina. AIDS. 2009;23:835-843.
63. Gazzard BG, Anderson J, Babiker A, et al. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9:563-608.
64. Steward WT, Remien RH, Higgins JA, et al. Behavior change following diagnosis with acute/early HIV infection-a move to serosorting with other HIV-infected individuals. The NIMH Multisite Acute HIV Infection Study: III. AIDS Behav. 2009;13:1054-1060.
65. Pettifor A, MacPhail C, Corneli A, et al. Continued high risk sexual behavior following diagnosis with acute HIV infection in South Africa and Malawi: implications for prevention. AIDS Behav. 2011;15:1243-1250.
66. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921-929.
67. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
68. Rieder P, Joos B, von Wyl V, et al. HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS. 2010;24:1177-1183.
69. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355: 2283-2296.
70. Harrington M, Carpenter CC. Hit HIV-1 hard, but only when necessary. Lancet. 2000;355:2147-2152.
71. Archin NM, Vaidya NK, Kuruc JD, et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci USA. 2012;109: 9523-9528.
72. Bacchus C, Hocqueloux L, Avettand-Fenoel V, et al. Distribution of the HIV reservoir in patients spontaneously controlling HIV infection after treatment interruption. Presented Mar 5-8, 2012 at the 19th International AIDS Conference, Seattle, WA.
73. Cellerai C, Harari A, Stauss H, et al. Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors. PLoS One. 2011;6:e18164.
74. Desquilbet L, Goujard C, Rouzioux C, et al. Does transient HAART during primary HIV-1 infection lower the virological set-point? AIDS. 2004;18:2361-2369.
75. Evering TH, Mehandru S, Racz P, et al. Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog. 2012;8: e1002506.
76. Fidler S, Fraser C, Fox J, et al. Comparative potency of three antiretroviral therapy regimes in primary HIV infection. AIDS. 2006;20: 247-252.
77. Fidler S, Fox J, Touloumi G, et al. Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort. AIDS. 2007;21:1283-1291.
78. Gay C, Dibben O, Anderson JA, et al. Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. PLoS One. 2011;6:e19617.
79. Gianella S, von Wyl V, Fischer M, et al. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antivir Ther. 2011;16:535-545.
80. Goujard C, Emilie D, Roussillon C, et al. Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial. AIDS. 2012;26:1895-1905.
81. Goujard C, Girault I, Rouzioux C, et al. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther. 2012;17: 1001-1009.
82. Grijsen ML, Koster GT, van Vonderen M, et al. Temporary antiretro-viral treatment during primary HIV-1 infection has a positive impact on health-related quality of life: data from the Primo-SHM cohort study. HIV Med. 2012;13:630-635.
83. Grijsen ML, Steingrover R, Wit FW, et al. No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med. 2012;9:e1001196.
84. Hecht FM, Wang L, Collier A, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis. 2006;194:725-733.
85. Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al. Long-term immu-novirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS. 2010; 24:1598-1601.
86. Hoen B, Cooper DA, Lampe FC, et al. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clin Infect Dis. 2007;45:381-390.
87. Hogan CM, Degruttola V, Sun X, et al. The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis. 2012;205:87-96.
88. Jain V, Hartogensis W, Bacchetti P, et al. ART initiation during acute/early HIV infection compared to later ART initiation with improved immunologic and virologic parameters during suppressive ART. Presented Feb 27-Mar 2, 2011 at the 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA.
89. Jansen CA, De Cuyper IM, Steingrover R, Jurriaans S, Sankatsing SU, Prins JM, et al. Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions. AIDS. 2005;19:1145-1154.
90. Kaufmann DE, Lichterfeld M, Altfeld M, et al. Limited durability of viral control following treated acute HIV infection. PLoS Med. 2004;1:e36.
91. Kinloch-De Loes S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med. 1995;333:408-413.
92. Koegl C, Wolf E, Hanhoff N, et al. Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort. Eur J Med Res. 2009;14:277-283.
93. Lampe FC, Porter K, Kaldor J, et al. Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study. Antivir Ther. 2007;12: 189-193.
94. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med. 2013;368:218-230.
95. Lodi S, Meyer L, Kelleher AD, et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med. 2012;172:1252-1255.
96. Markowitz M, Jin X, Hurley A, et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis. 2002;186:634-643.
97. Mehandru S, Poles MA, Tenner-Racz K, et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med. 2006;3:e484.
98. Moir S, Buckner CM, Ho J, et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood. 2010;116:5571-5579.
99. Niu MT, Bethel J, Holodniy M, et al. Zidovudine treatment in patients with primary (acute) human immunodeficiency virus type 1 infection: a randomized, double-blind, placebo-controlled trial. DATRI 002 Study Group. Division of AIDS Treatment Research Initiative. J Infect Dis. 1998;178:80-91.
100. Oxenius A, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD, Whelan JA, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A. 2000;97:3382-3387.
101. Pantazis N, Touloumi G, Vanhems P, et al. The effect of antiretroviral treatment of different durations in primary HIV infection. AIDS. 2008; 22:2441-2450.
102. Prazuck T, Lafeuillade A, Hocqueloux L, et al. Can HAART at early acute HIV infection benefit the immune-virology outcome despite subsequent treatment cessation? Presented Feb 3-6, 2008 at the 15th Conference on Retroviruses and Opportunistic Infections; 2008, Boston, MA.
103. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523-526.
104. Rosenberg ES, Graham BS, Chan ES, et al. Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. PLoS One. 2010;5:e10555.
105. Sáez-Cirión A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013;9:e1003211.
106. Seng R, Goujard C, Desquilbet L, et al. Rapid CD4+ cell decrease after transient cART initiated during primary HIV infection (ANRS PRIMO and SEROCO cohorts). J Acquir Immune Defic Syndr. 2008;49:251-258.
107. SPARTAC Trial Investigators. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med. 2013;368:1-11.
108. Steingrover R, Pogany K, Fernandez Garcia E, et al. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS. 2008;22: 1583-1588.
109. Steingrover R, Garcia EF, van Valkengoed IG, et al. Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection. AIDS Res Hum Retroviruses. 2010;26:379-387.
110. Streeck H, Jessen H, Alter G, et al. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis. 2006;194:734-739.
111. Tilling R, Kinloch S, Goh L-E, et al. Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS. 2002;16:589-596.
112. Vinikoor MJ, Cope A, Gay CL, et al. Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T cell activation. J Acquir Immune Defic Syndr. 2013. [Epub ahead of print].
113. Volberding P, Demeter L, Bosch RJ, et al. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS. 2009;23:1987-1995.
114. Wyl V, Gianella S, Fischer M, et al. Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS One. 2011;6:e27463.
115. Younes SA, Trautmann L, Yassine-Diab B, et al. The duration of exposure to HIV modulates the breadth and the magnitude of HIV-specific memory CD4 T cells. J Immunol. 2007;178:788-797.
116. Clark SJ, Shaw GM. The acute retroviral syndrome and the pathogen-esis of HIV-1 infection. Semin Immunol. 1993;5:149-155.
117. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med. 1998;339:33-39.
118. McKellar MS, Cope AB, Gay CL, et al. Acute HIV-1 infection in the Southeastern United States: a cohort study. AIDS Res Hum Retrovi-ruses. 2013;29:121-128.
119. Socías ME, Sued O, Laufer N, et al. Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters. J Int AIDS Soc. 2011;14:40.
120. Henard S, Jeanmaire E, Nguyen Y, et al. Is total community viral load a robust predictive marker of the efficacy of the TasP strategy? J Acquir Immune Defic Syndr. 2012;61:400-402.
121. Chun TW, Fauci AS. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS. 2012;26:1261-1268.
122. Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol. 2000;18:665-708.
123. Pires A, Hardy G, Gazzard B, et al. Initiation of antiretroviral therapy during recent HIV-1 infection results in lower residual viral reservoirs. J Acquir Immune Defic Syndr. 2004;36:783-790.
124. Buzon M, Mclaren P, Seiss K, et al. Reduced HIV-1 reservoir size after 10 years of sup-pressive antiretroviral therapy in patients initiating treatment during primary infection. Presented Dec 6-9, 2011 at the Fifth International Workshop on HIV Persistence During Therapy; 2011; St Maarten, The Netherlands.
125. Saez-Cirion A, Hocqueloux L, Avettand-Fenoel V, et al. Long-term HIV-1 control after interruption of treatment initiated at the time of primary infection is associated to low cell-associated HIV DNA levels: ANRS VISCONTI Study. Presented Feb 27-Mar 2, 2011 at the 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA.
126. Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009; 360:692-698.
127. Persaud D, Gay H, Ziemniak C, et al. Functional HIV cure after very early ART of an infected infant. Presented Mar 3-6, 2013 at the 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA.
128. Rebeiro P, Althoff KN, Buchacz K, et al. Retention among North American HIV-infected persons in clinical care, 2000-2008. J Acquir Immune Defic Syndr. 2012. [Epub ahead of print].
129. University of Minnesota Clinical and Translational Science Institute. START-Strategic timing of Antiretroviral treatment. University of Minnesota Clinical and Translational Science Institute. Available at: http://insight.ccbr. umn.edu/start/. Accessed April 18 2013.
130. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. 2011:1-156.
131. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of anti-retroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/guidelines. Accessed February 12, 2013.
132. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321-333.